Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.73 |
| ▸ | ALPI | P09923 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | XIAP | P98170 | 1/20 | 0.73 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | LAP3 | P28838 | 3/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28940160 | 1.00 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL8609117 | 0.87 | SLC7A5 (0.96) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL8609120 | 0.87 | SLC7A5 (0.96) | SLC7A5ALPIPKMPTGS1XIAP | |
| D-Phenylalanine SCHEMBL28862316 | 0.85 | SLC7A5 (0.92) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28126466 | 0.85 | SLC7A5 (0.92) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL23159186 | 0.84 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL660503 | 0.84 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL1330932 | 0.84 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL8835931 | 0.84 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL660504 | 0.84 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | claimed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | claimed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | claimed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | claimed |
| US-5929103-A | ANTICARCINOGENIC AGENTS | DONG WHA PHARM. IND. CO., LTD. (KR) | 1999-07-27 | — | — | US | claimed |
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| US-20200317630-A1 | ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10689355-B2 | Anticancer agent | Kyoto Pharmaceuticals Industries, Ltd. (JP) | 2020-06-23 | — | — | US | disclosed |
| EP-3153508-B1 | NAPHTHOFURAN DERIVATIVES FOR USE AS ANTICANCER AGENTS | KYOTO PHARMA IND (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-10377730-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20180265489-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3153508-A1 | NOVEL ANTICANCER AGENT | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | SLC7A5 593/4885ALPI 804/4885PKM 3391/4885 |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | SLC7A5 2059/4885ALPI 881/4885PKM 851/4885 |
| US-20200317630-A1 | ANTICANCER AGENT | TP53, NTPCR, NQO1 | SLC7A5 403/4885ALPI 364/4885PKM 2754/4885 |
| US-11267797-B2 | Anticancer agent | TP53, NTPCR, NQO1 | SLC7A5 403/4885ALPI 364/4885PKM 2754/4885 |
| US-20180265489-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | SLC7A5 593/4885ALPI 804/4885PKM 3391/4885 |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | SLC7A5 593/4885ALPI 804/4885PKM 3391/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | SLC7A5 2059/4885ALPI 881/4885PKM 851/4885 |
| US-10689355-B2 | Anticancer agent | TP53, NTPCR, NQO1 | SLC7A5 403/4885ALPI 364/4885PKM 2754/4885 |
| US-10377730-B2 | Anticancer agent | TP53, NTPCR, NQO1 | SLC7A5 403/4885ALPI 364/4885PKM 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.